ABBV Congressional Stock Trades & Insider Buying (2026)

ABBV insider buying and selling over the past year

Insiders at AbbVie Inc. only sold stock in the open market over the past year: 3 Form 4 sales totaling $10.74M, against no open-market purchases.

Most of the selling was pre-scheduled: 2 of the 3 sales (66.7%) were flagged as Rule 10b5-1 plan trades, which are set up in advance and say less about an insider's current view than discretionary sales. Activity clustered in 2026-03 (2 trades) and 2026-02 (1 trades); the latest filing in this window is dated 2026-03-04. The average open-market sale price was $232.17; the last close of $285.42 is 22.9% above that level, so sellers left upside on the table. The single largest trade was a sale of 22,381 shares worth $5.15M on 2026-02-25. Since the most recent filing the stock has moved +20.8%, from $236.19.

Where ABBV trades relative to its one-year range

AbbVie Inc. closed at $285.42 on 2026-10-16, inside a one-year range of $197.38 to $285.42. That puts the stock near the top of its range, at 100.0% of the distance from low to high. Over one year the share price moved +25.8%, and over roughly three months +12.2%. Average daily volume over the last month was about 4,947,422 shares.

Across 137 companies in the same SEC industry group (SIC 28) with a full year of prices in Gemral Edge, the median one-year return was +12.0%. ABBV is ahead of that median and beat 67% of that peer group on this measure.

Members of Congress who traded ABBV

STOCK Act disclosures show 79 trades in ABBV by 24 members of Congress over five years (41 purchases, 38 sales), most recently on 2026-09-14. The most active traders were Ro Khanna (D-CA), 23 trades; Tommy Tuberville (R-AL), 7 trades; Josh Gottheimer (D-NJ), 6 trades; Lisa C. McClain (R-MI), 6 trades; Julia Letlow (R-LA), 4 trades.

By party the trades split 45 by Democrats, 34 by Republicans; by chamber, 68 from the House, 11 from the Senate.

ABBV lobbying disclosures

AbbVie Inc. appears in 9 Lobbying Disclosure Act filings between 2018 and 2018, with $3.20M in reported lobbying spend.

Compare ABBV with indexed peers from the same industry group

These peers have full Gemral Edge dossiers and the closest one-year price move to ABBV:

• UTHR one-year return +23.2%
• PFE one-year return +22.1%
• PRM one-year return +20.7%
• CL one-year return +20.5%
• AXTA one-year return +20.5%

Sources and method

Every figure above is computed from public filings stored in Gemral Edge, not estimated. Insider figures count only open-market purchases and sales reported on SEC Form 4; option exercises, grants and gifts are excluded because they do not reflect a decision to buy or sell at market prices.

• SEC EDGAR Form 4 (edge_insider_trades, codes P/S open-market only) — as of 2026-03-04
• edge_prices_eod (end-of-day close) — as of 2026-10-16
• House PTR / Senate eFD disclosures (edge_congress_trades) — as of 2026-09-14
• Senate LDA filings (edge_lobbying_filings)

ABBV data questions

Are ABBV insiders buying or selling stock?

Insiders at AbbVie Inc. only sold stock in the open market over the past year: 3 Form 4 sales totaling $10.74M, against no open-market purchases.

What is the one-year price range for ABBV?

Based on end-of-day closes through 2026-10-16, ABBV traded between $197.38 and $285.42, last closing at $285.42.

Has any member of Congress traded ABBV stock?

Yes. 24 members disclosed 79 trades in ABBV over five years; the most recent disclosed trade date is 2026-09-14.